- Home
- EQR vs UTHR Comparison
EQR vs UTHR Comparison
Compare EQR & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EQR | UTHR |
|---|---|---|
| Founded | 1993 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.5B | 20.3B |
| IPO Year | 1993 | 1999 |
Fundamental Metrics
Financial Performance| Metric | EQR | UTHR |
|---|---|---|
| Price | $63.10 | $507.19 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 11 | 12 |
| Target Price | $70.00 | ★ $495.08 |
| AVG Volume (30 Days) | ★ 2.1M | 472.2K |
| Earning Date | 02-02-2026 | 10-29-2025 |
| Dividend Yield | ★ 4.42% | N/A |
| EPS Growth | ★ 24.49 | 16.08 |
| EPS | 3.03 | ★ 26.38 |
| Revenue | $3,078,827,000.00 | ★ $3,128,400,000.00 |
| Revenue This Year | $5.10 | $13.64 |
| Revenue Next Year | $3.51 | $5.78 |
| P/E Ratio | $20.68 | ★ $19.51 |
| Revenue Growth | 4.69 | ★ 13.50 |
| 52 Week Low | $58.38 | $266.98 |
| 52 Week High | $75.86 | $519.99 |
Technical Indicators
Market Signals| Indicator | EQR | UTHR |
|---|---|---|
| Relative Strength Index (RSI) | 63.31 | 61.16 |
| Support Level | $60.89 | $498.76 |
| Resistance Level | $62.52 | $519.99 |
| Average True Range (ATR) | 0.95 | 11.19 |
| MACD | 0.21 | 0.18 |
| Stochastic Oscillator | 98.83 | 69.81 |
Price Performance
Historical ComparisonAbout EQR Equity Residential of Beneficial Interest
Equity Residential owns a portfolio of 312 apartment communities with over 84,000 units and is developing two additional properties with 655 units. The company focuses on owning large, high-quality properties in the urban and suburban submarkets of Southern California, San Francisco, Washington, D.C., New York, Seattle, and Boston.
About UTHR United Therapeutics Corporation
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.